0.01
+25.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CONNEQT Health
Its shares trade on ASX under the ticker CQT.AX. It has been listed since 9 November 2005. In the fiscal year to 30 June 2025, it reported revenue of A$3.6m and a net loss of A$18.2m. At that date it held total assets of A$9.3m and shareholders' equity of A$633,510.
CardieX Ltd. engages in the design, manufacture, and marketing of medical devices which is used for cardiovascular management. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-11-09. The firm operates through three segments: Americas, which includes global pharmaceutical trials business; Europe, which includes Middle East and Africa, and Asia Pacific, which includes Asia and Australia/New Zealand. The firm's clinical trial services, include study protocol assistance, study-specific user manual, operator training and certification, study-specific training materials, automated data transfer for expert over-read, quality assurance, ongoing data management, technical support and sponsor-defined data transfers. The firm also offers SphygmoCor technology, which is used in clinical trials for a range of therapeutic areas, including hypertension, renal disease, heart failure, inflammatory processes, diabetes and chronic obstructive pulmonary disease (COPD).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 9 Nov 2005
- Employees
- 26
- Website
- cardiex.com ↗
Leadership
Pay as last reported
- Mr. Niall CairnsExecutive Chairman of the Board, since 2017A$759,325
- Mr. Craig CooperChief Executive Officer, Executive Director, since 2017A$1.2m
- Mr. Steve BraatenVice President - Operations
- Ms. Catherine LiaoChief Strategy Officer
- Ms. Louisa HoCompany Secretary
- Mr. Randall NelsonIndependent Non-Executive DirectorA$86,760
- Mr. Charlie TaylorNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CardieX Ltd designs medical devices for cardiovascular management in the Health Care sector.
- The company employs 26 full-time staff members to support its clinical trial services.
- SphygmoCor technology is utilized in clinical trials for hypertension and heart failure treatment.
Weaknesses
- The firm operates with a small workforce of only 26 employees globally.
- CONNEQT Health Ltd has been listed on the market since 9 November 2005.
- The company is headquartered in Sydney, New South Wales, Australia, which may limit local reach.
Opportunities
- The Americas segment includes a global pharmaceutical trials business offering expansion potential.
- The Europe segment covers the Middle East and Africa regions for growth.
- The Asia Pacific segment includes Asia and Australia/New Zealand for market development.
Threats
- The company faces risks in the competitive cardiovascular management device market.
- Regulatory changes in the Health Care sector could impact clinical trial services.
- Economic fluctuations in the Americas, Europe, and Asia Pacific segments affect revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.